Packaging Coordinators, Inc. (PCI) has reached a definitive agreement to acquire Penn Pharmaceutical Services Limited (Penn Pharma). Penn Pharma is headquartered in Tredegar, Wales in the United Kingdom, with regional offices in New Hope, Pennsylvania and Tokyo, Japan. It offers both drug development and manufacturing services, including Clinical and Commercial dosage form manufacturing, as well as Clinical Packaging, Labeling, and global Storage, Distribution and Return Drug Services. Recently, Penn Pharma opened a new contained manufacturing facility in response to market need for specialist containment solutions for the development and manufacturing of solid oral dose products containing highly potent compounds. This year, Penn launched a capacity expansion project for large scale commercial manufacturing and packaging.
Penn Pharma’s drug development, manufacturing, and packaging services complement PCI’s strength in Clinical Trial and Commercial supply services. PCI has announced several key investments recently including Cold Chain infrastructure expansions for both storage and logistics as well as support for refrigerated packaging operations. PCI will also open a 97,000 square foot state-of-the-art North American Storage and Distribution facility for investigational products in September of this year.
“We are very excited about adding Penn Pharma’s expertise and experience in drug development,” said Bill Mitchell, President and CEO of PCI. “Penn Pharma is a recognized leader in this area and the opportunity to combine forces adds significant value for our clients. With Penn Pharma’s services, we can partner with clients at the very earliest stages of drug development to support them with drug formulation, analytical development, drug manufacturing, clinical packaging, global distribution, and ultimately supporting the product’s commercial launch. This addition expands our vision of lifecycle support from clinical trials through commercialization for our clients’ lifesaving therapies.”